Profile data is unavailable for this security.
About the company
Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
- Revenue in EUR (TTM)126.63m
- Net income in EUR17.45m
- Incorporated--
- Employees136.00
- LocationPharmanutra SpAVia delle Lenze n. 216/BPISA 56122ItalyITA
- Websitehttps://www.pharmanutra.it/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pulike Biological Engineering Inc | 133.83m | 17.42m | 589.92m | 1.55k | 33.44 | 1.89 | -- | 4.41 | 0.4204 | 0.4204 | 3.22 | 7.45 | 0.3571 | 2.68 | 3.03 | 711,690.80 | 4.65 | 6.79 | 5.41 | 8.00 | 57.65 | 62.55 | 13.02 | 16.34 | 2.51 | 15.83 | 0.0005 | 61.54 | -16.77 | 9.47 | -46.82 | -3.21 | 7.28 | 14.87 |
| Shanghai Xiao Fang Pharmaceutical Co Ltd | 61.18m | 25.88m | 590.80m | 404.00 | 22.70 | 4.62 | -- | 9.66 | 1.33 | 1.33 | 3.16 | 6.57 | 0.3795 | 3.71 | 4.85 | 1,248,981.00 | 16.06 | -- | 19.02 | -- | 65.40 | -- | 42.31 | -- | 3.47 | -- | 0.0017 | -- | 0.5748 | -- | 0.8074 | -- | -- | -- |
| Zeria Pharmaceutical Co Ltd | 466.35m | 39.11m | 599.46m | 1.75k | 13.22 | 0.9999 | 12.58 | 1.29 | 164.79 | 164.79 | 1,964.97 | 2,178.21 | 0.5366 | 1.27 | 3.21 | 49,607,640.00 | 4.49 | 4.67 | 6.99 | 7.47 | 72.76 | 72.17 | 8.37 | 9.02 | 0.9739 | 11.41 | 0.2984 | 28.75 | 15.30 | 7.64 | 28.52 | 27.71 | 16.51 | 6.69 |
| Tibet Weixinkang Pharmaceutical Co Ltd | 141.65m | 26.93m | 600.41m | 689.00 | 22.16 | 3.24 | -- | 4.24 | 0.5136 | 0.5136 | 2.71 | 3.51 | 0.608 | 11.75 | 6.71 | 1,695,637.00 | 11.56 | 10.05 | 14.30 | 13.45 | 58.42 | 51.50 | 19.01 | 13.72 | 3.93 | -- | 0.0058 | 52.31 | -1.69 | 11.90 | 15.02 | 34.62 | 5.91 | 50.02 |
| Shilpa Medicare Ltd | 124.06m | 12.69m | 601.59m | 898.00 | 47.40 | 2.67 | 25.65 | 4.85 | 7.02 | 7.02 | 68.61 | 124.61 | 0.4058 | 0.9867 | 3.41 | 14,939,110.00 | 4.15 | 2.02 | 5.14 | 2.61 | 71.63 | 60.07 | 10.23 | 5.17 | 0.7867 | 4.09 | 0.1957 | 9.89 | 11.71 | 7.22 | 145.63 | -12.90 | 16.09 | -- |
| ASP Isotopes Inc | 7.04m | -88.60m | 601.69m | 136.00 | -- | 7.22 | -- | 85.51 | -1.43 | -1.43 | 0.1124 | 0.7932 | 0.0541 | 8.86 | 0.884 | 61,642.43 | -68.21 | -- | -85.13 | -- | 23.00 | -- | -1,261.23 | -- | 6.10 | -0.6787 | 0.5382 | -- | 857.03 | -- | -115.60 | -- | -- | -- |
| Tong Ren Tang Technologies Co Ltd | 840.27m | 52.21m | 603.87m | 3.89k | 11.57 | 0.6844 | 4.57 | 0.7187 | 0.3796 | 0.3796 | 6.11 | 6.41 | 0.482 | 0.8615 | 6.00 | 1,960,341.00 | 5.47 | 7.44 | 8.57 | 12.07 | 39.82 | 42.21 | 11.34 | 15.10 | 2.79 | -- | 0.1913 | 39.34 | 7.18 | 10.15 | -11.59 | 4.55 | -8.30 | 3.37 |
| Guizhou Sanli Pharmaceutical Co Ltd | 210.45m | 19.48m | 607.35m | 2.85k | 30.87 | 3.39 | -- | 2.89 | 0.3969 | 0.3969 | 4.26 | 3.61 | 0.5877 | 1.73 | 2.98 | 608,615.00 | 5.58 | 10.78 | 8.75 | 15.70 | 68.09 | 70.69 | 9.49 | 15.41 | 1.11 | 27.57 | 0.345 | 35.70 | 31.16 | 19.40 | -6.38 | 15.54 | 41.35 | -- |
| Pharmanutra SpA | 126.63m | 17.45m | 612.81m | 136.00 | 34.82 | 9.18 | 30.64 | 4.84 | 1.82 | 1.82 | 13.14 | 6.89 | 1.08 | 0.4411 | 4.92 | 1,101,148.00 | 14.72 | 17.26 | 19.66 | 22.90 | 96.83 | 96.06 | 13.68 | 17.09 | 1.86 | 680.62 | 0.2411 | 53.71 | 15.27 | 16.59 | 29.43 | 14.46 | -2.65 | 16.80 |
| Ocumension Therapeutics | 65.75m | -30.14m | 613.88m | 505.00 | -- | 1.39 | -- | 9.34 | -0.3746 | -0.3746 | 0.8176 | 5.05 | 0.1571 | 4.30 | 3.35 | 1,252,028.00 | -7.20 | -24.03 | -7.62 | -25.71 | 42.58 | 58.38 | -45.84 | -400.90 | 4.86 | -- | 0.0223 | -- | 69.38 | 365.95 | 29.36 | -- | 213.01 | -- |
| Tempo Scan Pacific Tbk PT | 681.34m | 75.00m | 624.10m | 4.40k | 8.32 | 1.33 | 6.35 | 0.916 | 332.96 | 332.96 | 3,025.00 | 2,081.51 | 1.07 | 3.75 | 9.03 | 3,044,214,000.00 | 12.14 | 10.71 | 16.37 | 14.66 | 37.60 | 35.87 | 11.31 | 9.06 | 2.51 | -- | 0.0944 | 43.45 | 4.08 | 4.43 | 22.96 | 21.17 | 3.64 | 20.11 |
| ZhuZhou QianJin Pharmaceutical Co., Ltd | 440.54m | 30.31m | 633.77m | 5.27k | 17.37 | 1.78 | -- | 1.44 | 0.6115 | 0.6115 | 8.87 | 5.98 | 0.7768 | 4.12 | 9.84 | 689,467.60 | 7.43 | 8.36 | 13.56 | 15.33 | 48.13 | 44.74 | 9.56 | 9.71 | 1.13 | -- | 0.0182 | 67.36 | -4.44 | 0.5863 | -27.98 | -4.75 | 3.10 | -6.36 |
Data as of Feb 10 2026. Currency figures normalised to Pharmanutra SpA's reporting currency: Euro EUR
12.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management)as of 31 Jan 2026 | 302.64k | 3.13% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 244.70k | 2.53% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Jan 2025 | 206.52k | 2.13% |
| Cr�dit Mutuel Asset Management SAas of 31 Dec 2024 | 106.15k | 1.10% |
| Arca Fondi SGR SpAas of 30 Dec 2025 | 100.76k | 1.04% |
| Mirabaud Asset Management Ltd.as of 30 Jun 2025 | 60.15k | 0.62% |
| Lupus alpha Asset Management AGas of 30 Jun 2025 | 53.00k | 0.55% |
| Kairos Partners SGR SpAas of 30 Jun 2025 | 51.01k | 0.53% |
| Polar Capital (America) Corp.as of 31 Dec 2025 | 50.91k | 0.53% |
| Amundi Asset Management SASU (Investment Management)as of 07 Jan 2026 | 44.50k | 0.46% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
